NM_000251.3:c.1818_1877delCAGCTTTGCTCACGTGTCAAATGGAGCACCTGTTCCATATGTACGACCAGCCATTTTGGA
Variant summary
Our verdict is Likely pathogenic. The variant received 6 ACMG points: 6P and 0B. PM1PM4PP3PP5
The NM_000251.3(MSH2):c.1818_1877delCAGCTTTGCTCACGTGTCAAATGGAGCACCTGTTCCATATGTACGACCAGCCATTTTGGA(p.Ser607_Glu626del) variant causes a disruptive inframe deletion change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. It is difficult to determine the true allele frequency of this variant because it is of type DEL_BIG, and the frequency of such variant types in population databases may be underestimated and unreliable. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Synonymous variant affecting the same amino acid position (i.e. V606V) has been classified as Benign.
Frequency
Consequence
NM_000251.3 disruptive_inframe_deletion
Scores
Clinical Significance
Conservation
Publications
- Lynch syndromeInheritance: AD Classification: DEFINITIVE, SUPPORTIVE Submitted by: G2P, ClinGen, Orphanet
- Lynch syndrome 1Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), Genomics England PanelApp, Ambry Genetics
- Muir-Torre syndromeInheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Genomics England PanelApp, Orphanet, G2P
- mismatch repair cancer syndrome 1Inheritance: AR Classification: DEFINITIVE, SUPPORTIVE Submitted by: ClinGen, Orphanet
- mismatch repair cancer syndrome 2Inheritance: AR Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), G2P
- ovarian cancerInheritance: AD Classification: STRONG Submitted by: Genomics England PanelApp
- malignant pancreatic neoplasmInheritance: AD Classification: MODERATE Submitted by: Genomics England PanelApp
- prostate cancerInheritance: AD Classification: MODERATE Submitted by: Ambry Genetics
- rhabdomyosarcomaInheritance: AR Classification: MODERATE Submitted by: Genomics England PanelApp
- breast cancerInheritance: AD Classification: NO_KNOWN Submitted by: Ambry Genetics
- hereditary breast carcinomaInheritance: AD Classification: NO_KNOWN Submitted by: ClinGen
Genome browser will be placed here
ACMG classification
Our verdict: Likely_pathogenic. The variant received 6 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| MSH2 | NM_000251.3 | c.1818_1877delCAGCTTTGCTCACGTGTCAAATGGAGCACCTGTTCCATATGTACGACCAGCCATTTTGGA | p.Ser607_Glu626del | disruptive_inframe_deletion | Exon 12 of 16 | ENST00000233146.7 | NP_000242.1 |
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| MSH2 | ENST00000233146.7 | c.1818_1877delCAGCTTTGCTCACGTGTCAAATGGAGCACCTGTTCCATATGTACGACCAGCCATTTTGGA | p.Ser607_Glu626del | disruptive_inframe_deletion | Exon 12 of 16 | 1 | NM_000251.3 | ENSP00000233146.2 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Hereditary cancer-predisposing syndrome Pathogenic:1Uncertain:1
The c.1818_1877del60 pathogenic mutation (also known as p.S607_E626del) is located in coding exon 12 of the MSH2 gene. This pathogenic mutation results from an in-frame 60 nucleotide deletion at positions 1818 to 1877. This results in the in-frame deletion of 20 amino acids at codons 607 to 626. This alteration is observed in an individual diagnosed with colorectal cancer and sebaceous epithelioma, which demonstrated loss of MSH2 and MSH6 expression on immunohistochemistry (IHC), and has a family history of Lynch-related tumors (Ambry internal data). Based on internal structural analysis using published crystal structures, S607_E626del removes a portion of MSH2 linking the MutS III and V domains, a region enriched in pathogenic variants (Warren JJ et al. Mol Cell, 2007 May;26:579-92; Ambry internal data). This variant was not reported in population-based cohorts in the Genome Aggregation Database (gnomAD). This amino acid region is generally well conserved through mammals. Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. -
This variant results in a deletion of 60 nucleotides in exon 12, resulting in an in-frame deletion of 20 amino acids from the MSH2 protein. To our knowledge, functional studies have not been reported for this variant. This deletion overlaps a region encoding a domain involved in interaction with the EXO1 and MSH6 proteins but the functional impact of this deletion is not known. This variant has not been reported in individuals affected with hereditary cancer in the literature. This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
Hereditary nonpolyposis colorectal neoplasms Uncertain:1
In summary, this is a novel in-frame deletion with uncertain impact on protein function. It has been classified as a Variant of Uncertain Significance. Experimental studies and prediction algorithms are not available for this variant. However, this deletion affects a region encoding the EXO1 and MSH6 interaction domains known to be important for the mismatch repair function of the MSH2 protein (PMID: 18822302, 9774676) This variant is not present in population databases (ExAC no frequency) and has not been reported in the literature in individuals with a MSH2-related disease. This sequence change deletes 60 nucleotides from exon 12 of the MSH2 mRNA (c.1818_1877del). This leads to the deletion of 20 amino acid residues in the MSH2 protein (p.Ser607_Glu626del) but otherwise preserves the integrity of the reading frame. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at